Investment Group Discloses 7.1% Stake Post-IPO, Includes Board Member
ODTX is trading near its 52-week low of $16.405 (7.4% above the low).
Summary
Dimension Management, L.P. and its affiliates, including a board member, disclosed a 7.1% ownership stake in Odyssey Therapeutics, representing an investment of over $45 million following the company's IPO.
Key Events · Ownership and Investor Activity · ODTX
-
Significant Ownership Stake
Dimension Management, L.P. and its affiliates reported a 7.1% beneficial ownership stake in Odyssey Therapeutics, totaling 3,333,516 shares.
-
Substantial Investment Value
The disclosed investment by the reporting group totals over $45 million, acquired through warrant exercises, preferred stock conversions, and a direct purchase in the IPO.
-
Board Representation
Nan Li, a member of the reporting group, currently serves on Odyssey Therapeutics' Board of Directors, indicating active involvement.
-
Post-IPO Disclosure
The stake was established on May 8, 2026, coinciding with the closing of the company's initial public offering.
Analysis · ODTX · Life Sciences
This Schedule 13D filing reveals that Dimension Management, L.P. and its affiliates, including board member Nan Li, have established a significant 7.1% beneficial ownership stake in Odyssey Therapeutics. The investment, totaling over $45 million, was primarily acquired through pre-IPO conversions and a direct purchase in the recent initial public offering. This disclosure, coming shortly after the company's IPO, represents a strong vote of confidence from a substantial institutional investor with direct board representation, signaling long-term commitment.
At the time of this filing, ODTX was trading at $17.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $834M. The 52-week trading range was $16.41 to $18.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.